scholarly journals P1.16-34 Association Between Skin Reactions and Clinical Benefit in Patients Treated with Anti-PD-1 Treatment for Advanced Non-Small Cell Lung Cancer

2019 ◽  
Vol 14 (10) ◽  
pp. S600-S601
Author(s):  
M. Aso ◽  
S. Sugawara ◽  
Y. Toi ◽  
J. Sugisaka ◽  
H. Ono ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Small Cell ◽  
Small Cell Lung ◽  
Skin Reactions

IMMUNOTHERAPY AND TOXICITY MANAGEMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

2021 ◽  
Vol 0 (39) ◽  
pp. 0-0
Author(s):  
Necmiye ÇÖMLEKÇİ ◽  
Dilek BAYKAL
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Retrospective Studies ◽  
Web Of Science ◽  
Early Period ◽  
Small Cell ◽  
Endocrine Disorders ◽  
Small Cell Lung ◽  
Skin Reactions

Aim: The aim of this review is to present an overview of the management of toxicities commonly seen in immunotherapy in patients with non-small cell lung cancer. Methods: “non-small cell lung cancer” OR “NSCLC” AND “PD-1” OR “PD-L1” AND from PubMed, Google Scholar, Web of Science databases to identify common toxicities based on the results of studies with patients with non-small cell lung cancer. A search was made with the keywords “retrospective”. Findings: A total of 12 retrospective studies with full texts in English were analyzed. According to the results of the study, it was found that toxicities such as skin reactions, pneumonitis, diarrhea, endocrine disorders, hepatitis, renal toxicity, neurotoxicity and atralgis were developed. Conclusions: In patients with non-small cell lung cancer receiving immunotherapy, it is important to detect toxicities in the early period so that the treatment continues without disruption. Oncology nurses have important roles in the prevent and early detection of toxicities, the education of the patient and their family, and the morning and evaluation of toxicity symptoms.

scholarly journals In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients

Cancers ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1271 ◽  
Author(s):  
Heeke ◽  
Benzaquen ◽  
Long-Mira ◽  
Audelan ◽  
Lespinet ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutational Burden ◽  
Potential Biomarker ◽  
Tumor Mutational Burden ◽  
Melanoma Patients

Tumor mutational burden (TMB) has emerged as an important potential biomarker for prediction of response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer (NSCLC). However, its in-house assessment in routine clinical practice is currently challenging and validation is urgently needed. We have analyzed sixty NSCLC and thirty-six melanoma patients with ICI treatment, using the FoundationOne test (FO) in addition to in-house testing using the Oncomine TML (OTML) panel and evaluated the durable clinical benefit (DCB), defined by >6 months without progressive disease. Comparison of TMB values obtained by both tests demonstrated a high correlation in NSCLC (R2 = 0.73) and melanoma (R2 = 0.94). The association of TMB with DCB was comparable between OTML (area-under the curve (AUC) = 0.67) and FO (AUC = 0.71) in NSCLC. Median TMB was higher in the DCB cohort and progression-free survival (PFS) was prolonged in patients with high TMB (OTML HR = 0.35; FO HR = 0.45). In contrast, we detected no differences in PFS and median TMB in our melanoma cohort. Combining TMB with PD-L1 and CD8-expression by immunohistochemistry improved the predictive value. We conclude that in our cohort both approaches are equally able to assess TMB and to predict DCB in NSCLC.

The limited clinical benefit of respiration gated radiotherapy (RGRT) in non-small cell lung cancer (NSCLC)

Lung Cancer ◽  
2010 ◽  
Vol 67 ◽  
pp. S30-S31 ◽  
Author(s):  
R. Muirhead ◽  
C. Featherstone ◽  
A. Duffton ◽  
K. Moore ◽  
S. McNee
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Small Cell ◽  
Small Cell Lung ◽  
Gated Radiotherapy

Vaccination of patients with advanced non-small cell lung cancer with an optimized cryptic hTERT peptide (Vx-001)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 7642-7642
Author(s):  
K. Kosmatopoulos ◽  
E. Bolonaki ◽  
A. Kotsakis ◽  
E. Papadimitraki ◽  
D. Agouraki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Median Overall Survival ◽  
Small Cell ◽  
Historical Control ◽  
Small Cell Lung ◽  
Skin Reactions ◽  
Local Skin

7642 Background: To evaluate the immunological and clinical efficacy of the optimized peptide TERT572Y (Vx-001) presented by HLA-A*0201 in patients with advanced non-small cell lung cancer (NSCLC). Methods: Twenty-two patients with residual (n=8) or progressive (n=14) advanced NSCLC following chemotherapy and/or radiotherapy received two subcutaneous injections of the optimized TERT572Y peptide followed by four injections of the native TERT572 peptide given every 3 weeks. Peptide-specific immune responses were monitored by Elispot assay and/or TERT572Y pentamer staining. Clinical outcome was compared with that of 22 case-matched historical control patients. Results: Thirteen (59%) out of 22 patients completed the vaccination program. Toxicity consisted primarily of local skin reactions. TERT572-specific CD8+ cells were detected in 16 (76.2%) out of 21 patients after the 2nd vaccination and 10 (90.9%) out of 11 patients after the 6th vaccination. Stable disease occurred in 8 (36.4%) patients with a median duration of 11.2 months. Patients with an early immunological response (n=16) had a significantly longer time to disease progression and overall survival than non-responders (n=5) (log-rank tests p=0.046 and p=0.012, respectively). The estimated median overall survival was 30.0 (range, 2.8–40.0) and 4.1 (range, 2.4–10.9) months for immunological responders and non-responders, respectively. Moreover, median overall survival was 30.6 months (95% CI:10.9–48.9) and 6.1 months (95% CI:4.4–7.8) for the vaccinated and case-matched historical control patients, respectively (p=0.074). Conclusions: TERT572Y peptide vaccine is well tolerated and effective in eliciting a specific T-cell immunity which seems to be associated with prolonged patients’ survival. No significant financial relationships to disclose.

RAD51Bme as predictive biomarker for PD-1 blockade response in non-small cell lung cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15235-e15235
Author(s):  
Inês Maria Guerreiro ◽  
Daniela Barros-Silva ◽  
Paula Lopes ◽  
Ana Luísa Cunha ◽  
João Lobo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Checkpoint Inhibitors ◽  
Predictive Biomarkers ◽  
Predictive Biomarker ◽  
Small Cell ◽  
Small Cell Lung ◽  
Dna Repair Gene

e15235 Background: Lung cancer (LC) cells frequently express high levels of programmed death-ligand 1 (PD-L1). Although these levels grossly correlate with likelihood of response to specific checkpoint inhibitors, prediction of response is rather imperfect and, thus, more accurate predictive biomarkers are mandatory. We examined the methylation profile of RAD51B, a DNA-repair gene, as candidate predictive biomarker for efficacy of anti-PD-1 therapy in patients with non-small cell lung cancer (NSCLC), correlating with patients’ outcome. Methods: PD-L1 immunoexpression and RAD51Bme levels were analysed in samples of NSCLC obtained from patients not treated with anti-PD-1 blockade (testing cohort) and patients treated with anti-PD-1 (validation cohort). Results: Of a total of 127 patients assessed, 58.3% depicted positivity for PD-L1 (PD-L1+). RAD51Bme levels significantly associated with PD-L1 immunoexpression. Patients with clinical benefit from immunotherapy disclosed higher RAD51Bme levels (p = 0.04) and significantly higher median progression free survival (PFS) (p = 0.02). PD-L1+ was also associated with longer overall survival (p = 0.03). Conclusions: We demonstrated that RAD51Bme levels might be combined with validated predictive biomarker PD-L1 immunostaining to select patients who will most likely experience clinical benefit from PD-1 blockade. The predictive value of RAD51Bme should be confirmed in prospective studies.

scholarly journals Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

BMC Cancer ◽  
2007 ◽  
Vol 7 (1) ◽  
Author(s):  
Hiroshi Yokouchi ◽  
Koichi Yamazaki ◽  
Ichiro Kinoshita ◽  
Jun Konishi ◽  
Hajime Asahina ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document